Business Responsibility Report

Overview

The report highlights the company's progress in FY21 research, including Masupirdine's preparation for a Phase 2/3 clinical trial. It also reports positive safety findings for Samelisant and a proposed expansion of its patient pool. The company invested US$6.18 mn in clinical trials during FY21.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2020-2021
Period: Ends 31 March 2021
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services